Holen Sie sich die Stockscreener-App
13.21
3.08%
-0.42
Vorhandelsmarkt:
13.51
0.30
+2.27%
Schlusskurs vom Vortag:
$13.63
Offen:
$13.575
24-Stunden-Volumen:
856.39K
Relative Volume:
0.76
Marktkapitalisierung:
$659.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-3.5799
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
-9.40%
1M Leistung:
+13.98%
6M Leistung:
+48.26%
1J Leistung:
-4.48%
1-Tages-Spanne:
$13.19
$13.83
1-Wochen-Bereich:
$13.19
$14.78
52-Wochen-Spanne:
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
13.21 | 680.87M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
Published on: 2025-08-04 07:21:19 - jammulinksnews.com
What are analysts’ price targets for KalVista Pharmaceuticals Inc. in the next 12 monthsBuild wealth steadily with proven stock picks - jammulinksnews.com
What institutional investors are buying KalVista Pharmaceuticals Inc. stockRapid wealth creation - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. stock overvalued or undervaluedMaximize your portfolio’s earning power - jammulinksnews.com
What analysts say about KalVista Pharmaceuticals Inc. stockInvest confidently with actionable market data - jammulinksnews.com
What are the technical indicators suggesting about KalVista Pharmaceuticals Inc.Unstoppable investment returns - jammulinksnews.com
When is KalVista Pharmaceuticals Inc. stock expected to show significant growthAchieve consistent profits with expert strategies - jammulinksnews.com
What drives KalVista Pharmaceuticals Inc. stock priceConsistently profitable trades - jammulinksnews.com
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastUnlock exclusive investment alerts - jammulinksnews.com
What is the risk reward ratio of investing in KalVista Pharmaceuticals Inc. stockAdvanced Screener Growth Plan For Every Investor - jammulinksnews.com
What are KalVista Pharmaceuticals Inc. company’s key revenue driversAI Powered Tracker That Work - jammulinksnews.com
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency - MSN
Published on: 2025-07-29 19:52:44 - metal.it
What makes KalVista Pharmaceuticals Inc. stock price move sharplyTriple Return Setup With Risk Control Explained - beatles.ru
Sebetralstat recommended for EU approval for treating HAE attacks - Angioedema News
What is the dividend policy of KalVista Pharmaceuticals Inc. stockBreakthrough investment results - jammulinksnews.com
KalVista Pharmaceuticals Faces Downgrade Due to Shrinking Market and Oral Competitor Threat - AInvest
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) - Seeking Alpha
Kalvista Pharmaceuticals shares rise 1.17% after-hours following positive CHMP opinion for sebetralstat. - AInvest
EMA’s CHMP adopts five orphans - BioCentury
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
European regulator recommends approval of first oral HAE treatment - Investing.com
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):